These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 16284425

  • 21. Usefulness of TSH receptor antibodies as biomarkers for Graves' ophthalmopathy: a systematic review.
    Seo S, Sánchez Robledo M.
    J Endocrinol Invest; 2018 Dec; 41(12):1457-1468. PubMed ID: 30194634
    [Abstract] [Full Text] [Related]

  • 22. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS, Zwicker H, Abbott EC, Douglas R, Givner ML, Gupta MK, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE.
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [Abstract] [Full Text] [Related]

  • 23. Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease.
    Aizawa Y, Yoshida K, Kaise N, Kaise K, Fukazawa H, Kiso Y, Mori K, Sayama N, Kikuchi K, Abe K.
    Clin Endocrinol (Oxf); 1995 May; 42(5):517-22. PubMed ID: 7621571
    [Abstract] [Full Text] [Related]

  • 24. Demonstration of anti-TSH antibody in TSH binding inhibitory immunoglobulin-positive sera of patients with Graves' disease.
    Ochi Y, Hamazu M, Kajita Y, Nagata A.
    Clin Endocrinol (Oxf); 2002 Mar; 56(3):405-12. PubMed ID: 11940054
    [Abstract] [Full Text] [Related]

  • 25. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.
    Tamaki H, Amino N, Aozasa M, Mori M, Tanizawa O, Miyai K.
    J Clin Endocrinol Metab; 1987 Aug; 65(2):324-30. PubMed ID: 2885336
    [Abstract] [Full Text] [Related]

  • 26. A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease.
    Hovens GC, Buiting AM, Karperien M, Ballieux BE, van der Pluijm G, Pereira AM, Romijn JA, Smit JW.
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):429-35. PubMed ID: 16584516
    [Abstract] [Full Text] [Related]

  • 27. The prognostic value of parallel measurements of thyrotropin binding inhibiting immunoglobulins (TBII) and thyroid adenylate cyclase stimulating antibodies (TSAb) in Graves' disease after longterm antithyroid treatment.
    Bliddal H, Bech K, Siersbaek-Nielsen K, Friis T.
    J Endocrinol Invest; 1983 Aug; 6(4):259-62. PubMed ID: 6139399
    [Abstract] [Full Text] [Related]

  • 28. Clinical significance of a sensitive assay for thyroid-stimulating antibodies in Graves' disease using polyethylene glycol at high concentrations and porcine thyroid cells.
    Kamijo K, Nagata A, Sato Y.
    Endocr J; 1999 Jun; 46(3):397-403. PubMed ID: 10503992
    [Abstract] [Full Text] [Related]

  • 29. Detection of low titre TBII in patients with Graves' disease using recombinant human TSH receptor.
    Morgenthaler NG, Nagata A, Katayama S, Bergmann A, Iitaka M.
    Clin Endocrinol (Oxf); 2002 Aug; 57(2):193-8. PubMed ID: 12153597
    [Abstract] [Full Text] [Related]

  • 30. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C, Cerrone D, Harii N, Thornton M, Kohn LD, Dagia NM, Bucci I, Carpentieri M, Di Nenno B, Di Blasio A, Vitti P, Monaco F, Napolitano G.
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
    [Abstract] [Full Text] [Related]

  • 31. Blocking-type anti-TSH receptor antibodies and relation to responsiveness to antithyroid drug therapy and remission in Graves' disease.
    Tada H, Mizuta I, Takano T, Tatsumi KI, Izumi Y, Hidaka Y, Amino N.
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):403-8. PubMed ID: 12641621
    [Abstract] [Full Text] [Related]

  • 32. The relationships between serum T3 index, thyroid volume, and thyroid stimulating, TSH receptor binding and thyroid growth stimulating antibodies in untreated Graves' disease.
    Bliddal H, Hegedüs L, Hansen JM, Bech K, van der Gaag R, Drexhage HA.
    Clin Endocrinol (Oxf); 1987 Jul; 27(1):75-84. PubMed ID: 2888551
    [Abstract] [Full Text] [Related]

  • 33. [Correlation between thyroid stimulating immunoglobulins and thyrotropin binding inhibitory immunoglobulins levels in patients with Graves' disease].
    Jonas M, Ambroziak U, Nauman J.
    Endokrynol Pol; 2006 Jul; 57(1):23-30. PubMed ID: 16575759
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment.
    Tamai H, Hirota Y, Kasagi K, Matsubayashi S, Kuma K, Iida Y, Konishi J, Okimura MC, Walter RM, Kumagai LF.
    J Clin Endocrinol Metab; 1987 Apr; 64(4):718-22. PubMed ID: 2434520
    [Abstract] [Full Text] [Related]

  • 39. Clinical course and thyroid stimulating hormone (TSH) receptor antibodies during surgical treatment of Graves' disease.
    Mori Y, Matoba N, Miura S, Sakai N, Taira Y.
    World J Surg; 1992 Apr; 16(4):647-52; discussion 652-3. PubMed ID: 1357830
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.